📰 Briggs Morrison News
Briggs Morrison News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Briggs Morrison. Real-time updates on events, politics, business and more.
November 6, 2023
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) has received a consensus rating of “Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have issued a report on the stock in […]
October 9, 2023
StockNews.com initiated coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a research note published on Thursday morning. The brokerage issued a sell rating on the stock. Several other equities analysts have also commented on the stock. HC Wainwright raised their target price on shares of Syndax Pharmaceuticals from $38.00 to $42.00 and […]
October 3, 2023
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its price target cut by equities researchers at Robert W. Baird from $32.00 to $28.00 in a research note issued on Tuesday, FlyOnTheWall reports. Robert W. Baird’s price target would suggest a potential upside of 107.41% from the stock’s current price. SNDX has been the subject of […]
October 3, 2023
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its price target hoisted by investment analysts at Guggenheim from $42.00 to $43.00 in a note issued to investors on Tuesday, FlyOnTheWall reports. Guggenheim’s target price suggests a potential upside of 218.52% from the stock’s current price. SNDX has been the subject of a number of other […]
October 3, 2023
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its price target lowered by Scotiabank from $39.00 to $36.00 in a research report issued on Tuesday, FlyOnTheWall reports. Scotiabank’s target price suggests a potential upside of 166.67% from the company’s current price. SNDX has been the topic of several other research reports. B. Riley upped their […]
September 17, 2023
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have been assigned a consensus recommendation of “Buy” from the nine analysts that are presently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued a report on the […]
September 17, 2023
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have been assigned an average recommendation of “Buy” from the nine brokerages that are covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued ratings on the […]
September 7, 2023
Axiom Investors LLC DE acquired a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 28,195 shares of the company’s stock, valued at approximately $595,000. A number of other hedge funds […]
August 23, 2023
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued a report on […]
August 23, 2023
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have earned an average rating of “Buy” from the nine analysts that are currently covering the company, MarketBeat reports. Nine analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year […]